[1] REBELLO R J, OING C, KNUDSEN K E, et al.Prostate cancer[J].Nat Rev Dis Primers, 2021, 7(1):9-10.
[2] CHANG J, CHAUDHURI O.Beyond proteases:basement membrane mechanics and cancer invasion[J].J Cell Biol, 2019, 218(8):2456-2469.
[3] NILAND S, RISCANEVO A X, EBLE J A.Matrix metalloproteinases shape the tumor microenvironment in cancer progression[J].Int J Mol Sci, 2021, 23(1):146.
[4] JING M, CHEN X, QIU H, et al.Insights into the immunomodulatory regulation of matrix metalloproteinase at the maternal-fetal interface during early pregnancy and pregnancy-related diseases[J].Front Immunol, 2023, 13:1067661.
[5] ALMEIDA L G N, THODE H, ESLAMBOLCHI Y, et al.matrix metalloproteinases:from molecular mechanisms to Physiology, Pathophysiology, and Pharmacology[J].Pharmacol Rev, 2022, 74(3):712-768.
[6] 竺梦霞, 麦筱莉, 朱斌.双能量CT在前列腺癌骨转移诊断中的应用进展[J].东南大学学报(医学版), 2022, 41(1):159-162.
[7] MURRAY N P, REYES E, SALAZAR A, et al.The expression of matrix-metalloproteinase-2 in bone marrow micro-metastasis is associated with the presence of circulating prostate cells and a worse prognosis in men treated with radical prostatectomy for prostate cancer[J].Turk J Urol, 2020, 46(3):186-195.
[8] GANGULY S S, HOSTETTER G, TANG L, et al.Notch3 promotes prostate cancer-induced bone lesion development via MMP-3[J].Oncogene, 2020, 39(1):204-218.
[9] TELLMAN T V, CRUZ L A, GRINDEL B J, et al.Cleavage of the perlecan-semaphorin 3A-plexin A1-neuropilin-1(PSPN) complex by matrix metalloproteinase 7/matrilysin triggers prostate cancer cell dyscohesion and migration[J].Int J Mol Sci, 2021, 22(6):3218.
[10] MA J B, BAI J Y, ZHANG H B, et al.Downregulation of collagen COL4A6 is associated with prostate cancer progression and metastasis[J].Genet Test Mol Biomarkers, 2020, 24(7):399-408.
[11] LIANG Z, CAO J, TIAN L, et al.Aromatase-induced endogenous estrogen promotes tumour metastasis through estrogen receptor-α/matrix metalloproteinase 12 axis activation in castration-resistant prostate cancer[J].Cancer Lett, 2019, 467:72-84.
[12] WANG Y, ZHANG Y X, KONG C Z, et al.Loss of P53 facilitates invasion and metastasis of prostate cancer cells[J].Mol Cell Biochem, 2013, 384(1-2):121-127.
[13] WANG S W, TAI H C, TANG C, et al.Melatonin impedes prostate cancer metastasis by suppressing MMP-13 expression[J].J Cell Physiol, 2021, 236(5):3979-3990.
[14] KIM S, KANG M, KO J.Small leucine zipper protein promotes the metastasis of castration-resistant prostate cancer through transcriptional regulation of matrix metalloproteinase-13[J].Carcinogenesis, 2021, 42(8):1089-1099.
[15] LI N, DHAR S S, CHEN T, et al.JARID1D is a suppressor and prognostic marker of prostate cancer invasion and metastasis[J].Cancer Res, 2016, 76(4):831-843.
[16] EIRO N, MEDINA A, GONZALEZ L O, et al.Evaluation of matrix metalloproteases by artificial intelligence techniques in negative biopsies as new diagnostic strategy in prostate cancer[J].Int J Mol Sci, 2023, 24(8):7022.
[17] FONTANA F, ANSELMI M, LIMONTA P.Adipocytes reprogram prostate cancer stem cell machinery[J].J Cell Commun Signal, 2023, 17(3):915-924.
[18] LAURENT V, TOULET A, ATTANE C, et al.Periprostatic adipose tissue favors prostate cancer cell invasion in an obesity-dependent manner:role of oxidative stress[J].Mol Cancer Res, 2019, 17(3):821-835.
[19] YANG B B, ZHANG D X, QIAN J H, et al.Chelerythrine suppresses proliferation and metastasis of human prostate cancer cells via modulating MMP/TIMP/NF-κB system[J].Mol Cell Biochem, 2020, 474(1-2):199-208.
[20] KUO P T, LIN T P, LIU L C, et al.Penta-O-galloyl-beta-D-glucose suppresses prostate cancer bone metastasis by transcriptionally repressing EGF-induced MMP-9 expression[J].J Agric Food Chem, 2009, 57(8):3331-3339.
[21] CHEN Y, ZHENG L, LIU J, et al.Shikonin inhibits prostate cancer cells metastasis by reducing matrix metalloproteinase-2/-9 expression via AKT/mTOR and ROS/ERK1/2 pathways[J].Int Immunopharmacol, 2014, 21(2):447-455.
[22] YANG J, WANG C, ZHANG Z, et al.Curcumin inhibits the survival and metastasis of prostate cancer cells via the Notch-1 signaling pathway[J].APMIS, 2017, 125(2):134-140.
[23] BRUNI-CARDOSO A, JOHNSON L C, VESSELLA R L, et al.Osteoclast-derived matrix metalloproteinase-9 directly affects angiogenesis in the prostate tumor-bone microenvironment[J].Mol Cancer Res, 2010, 8(4):459-470.
[24] LONDON C A, SEKHON H S, ARORA V, et al.A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity[J].Cancer Gene Ther, 2003, 10(11):823-832.
[25] FRIELING J S, LI T, TAURO M, et al.Prostate cancer-derived MMP-3 controls intrinsic cell growth and extrinsic angiogenesis[J].Neoplasia, 2020, 22(10):511-521.
[26] CHEN F, WANG M, BAI J, et al.Role of RUNX3 in suppressing metastasis and angiogenesis of human prostate cancer[J].PLoS One, 2014, 9(1):e86917.
[27] BACI D, BRUNO A, CASCINI C, et al.Acetyl-L-Carnitine downregulates invasion (CXCR4/CXCL12, MMP-9) and angiogenesis (VEGF, CXCL8) pathways in prostate cancer cells:rationale for prevention and interception strategies[J].J Exp Clin Cancer Res, 2019, 38(1):464.
[28] IIHAN S, DILEKCI G, GUNER A, et al.Newly synthesized benzimidazoles inhibit vascular endothelial growth factor and matrix metalloproteinase-2 and-9 levels in prostate cancer cells[J].Anticancer Agents Med Chem, 2022, 22(11):2109-2115.
[29] OGUIC R, MOZETIC V, TESAR E C, et al.Matrix metalloproteinases 2 and 9 immunoexpression in prostate carcinoma at the positive margin of radical prostatectomy specimens[J].Patholog Res Int, 2014, 2014:262195.
[30] OLCZAK M, ORZECHOWSKA M J, BEDNAREK A K, et al.The transcriptomic profiles of ESR1 and MMP3 stratify the risk of biochemical recurrence in primary prostate cancer beyond clinical features[J].Int J Mol Sci, 2023, 24(9):8399.
[31] JABOIN J J, HWANG M, LOPATER Z, et al.The matrix metalloproteinase-7 polymorphism rs10895304 is associated with increased recurrence risk in patients with clinically localized prostate cancer[J].Int J Radiat Oncol Biol Phys, 2011, 79(5):1330-1335.
[32] HSIEH C Y, CHOU Y E, LIN C Y, et al.Impact of matrix metalloproteinase-11 gene polymorphisms on biochemical recurrence and clinicopathological characteristics of prostate cancer[J].Int J Environ Res Public Health, 2020, 17(22):8603.
[33] ESCAFF S, FERNANDEZ J M, GONZALEZ L O, et al.Study of matrix metalloproteinases and their inhibitors in prostate cancer[J].Br J Cancer, 2010, 102(5):922-929.
[34] KUMAR B, KOUL S, KHANDRIKA L, et al.Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype[J].Cancer Res, 2008, 68(6):1777-1785.
[35] SHARIFTABRIZI A, KHORRAMIZADEH M R, SAADAT F, et al.Concomitant reduction of matrix metalloproteinase-2 secretion and intracellular reactive oxygen species following anti-sense inhibition of telomerase activity in PC-3 prostate carcinoma cells[J].Mol Cell Biochem, 2005, 273(1-2):109-116.
[36] NGUYEN H L, ZUCKER S, ZARRABI K, et al.Oxidative stress and prostate cancer progression are elicited by membrane-type 1 matrix metalloproteinase[J].Mol Cancer Res, 2011, 9(10):1305-1318.
[37] GUCCINI I, REVANDKAR A, DAMBROSIO M, et al.Senescence reprogramming by TIMP1 deficiency promotes prostate cancer metastasis[J].Cancer Cell, 2021, 39(1):68-82.
[38] EICHAER W K, TONET-FURIOSO A C, JUNIOR G S M, et al.Serum levels of matrix metalloproteinase-1 in brazilian patients with benign prostatic hyperplasia or prostate cancer[J].Curr Gerontol Geriatr Res, 2020, 2020:6012102.
[39] CICCO C D, RAVASI L, ZORZINO L, et al.Circulating levels of VCAM and MMP-2 may help identify patients with more aggressive prostate cancer[J].Curr Cancer Drug Targets, 2008, 8(3):199-206.
[40] 周金才, 居峰, 倪颖, 等.前列腺健康指数在不同tPSA区间段诊断前列腺癌的临床价值研究[J].现代医学, 2023, 51(7):918-922.
[41] SZARVAS T, BECKER M, DORP F V, et al.Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy[J].Int J Cancer, 2011, 128(6):1486-1492.
[42] SZARVAS T, SEVCENCO S, MODOS O, et al.Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer[J].BJU Int, 2018, 122(4):695-704.
[43] CHENG T, LI F, WEI R, et al.MMP26:a potential biomarker for prostate cancer[J].J Huazhong Univ Sci Technolog Med Sci, 2017, 37(6):891-894. 《现代医学》唯一投稿网址:www.xdyx.org.cn |
